resolvin D2

Resolvin D2 is a specialized pro-resolving lipid mediator of the resolvin family, biosynthesized from the omega-3 fatty acid docosahexaenoic acid (DHA) via sequential oxygenation by 15- and 5-lipoxygenase. It exhibits potent anti-inflammatory and pro-resolving activity, promoting the resolution of inflammation, modulating immune cell function, and facilitating tissue regeneration. Mechanistically, resolvin D2 activates the G protein-coupled receptor GPR18 (also known as DRV2), leading to a switch of macrophages toward an anti-inflammatory phenotype, increased secretion of pro-myogenic factors, and direct enhancement of myogenic cell differentiation. Preclinical models demonstrate activity in reducing inflammation, promoting muscle regeneration, and alleviating inflammatory pain. Resolvin D2 is under investigation as a therapeutic candidate for conditions driven by chronic inflammation, including Duchenne muscular dystrophy and pain syndromes[1][2][3][9].

Other names

7S,16R,17S-trihydroxy-4Z,8E,10Z,12E,14E,19Z-docosahexaenoic acid7(S),16(R),17(S)-Resolvin D2(4Z,7S,8E,10Z,12E,14E,16R,17S,19Z)-7,16,17-trihydroxydocosa-4,8,10,12,14,19-hexaenoic acid810668-37-2